Author:
Maggiolo Franco,Caputo Sergio Lo,Bonora Stefano,Borderi Marco,Cingolani Antonella,D’Ettorre Gabriella,Di Biagio Antonio,Di Giambenedetto Simona,Gervasoni Cristina,Guaraldi Giovanni,Maggi Paolo,Taramasso Lucia
Abstract
ABSTRACTBackgroundModern antiretroviral therapy (ART) offers several treatment options characterized by high efficacy and tolerability, and new strategies with new drugs are now available for the treatment of HIV infection. As definitive data on the long-term success of these new strategies are lacking, a panel of infectious diseases specialists was convened to develop a consensus on how to tailor and follow in time a person-centered ART approach.MethodsPanelists used a Delphi technique to develop a list of statements describing preferred management approaches for ART and patient monitoring and quality of life evaluation. Panelists provided level of agreement and feedback on consensus statements generated and refined them from the first round through 2 subsequent rounds of voting.ResultsNinety infectious diseases specialists from different Infectious Diseases Centres in Italy participated in the consensus process. A consensus was reached on virological and immunological parameters to use to monitor long term efficacy of antiretroviral treatment, while there was no consensus on the use of specific inflammation and immune-activation markers in clinical routine. The panel agreed on the need of an antiretroviral treatment with the lowest impact on bone, kidney and cardiovascular toxicity and on the utility of quality of life monitoring during the standard follow up of people living with HIV.ConclusionsThe consensus statements developed by a panel of infectious diseases specialists may provide guidance to practitioners for a person-centered approach aimed at obtaining long-term virological and clinical success for people living with HIV.Key pointsA panel of experts in the care of HIV infection expressed their consensus on which could be the best strategy to achieve and maintain long-term effectiveness in course of antiretroviral therapy, using Delphi methodology.
Publisher
Cold Spring Harbor Laboratory
Reference96 articles.
1. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents., A Working Group of the Office of AIDS Research, Advisory Council (OARAC). Guidelines for the Use of Antiretro-viral Agents in Adults and Adolescents with HIV. Available at: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf.
2. EACS European Aids Clinical Society. Guidelines. Version 11.0. October 2021. Available at: https://www.eacsociety.org/media/final2021eacsguidelinesv11.0_oct2021.pdf.
3. Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials;J Acquir Immune Defic Syndr,2020
4. Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies;The Lancet HIV,2019
5. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial